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A B S T R A C T
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide (Aβ) and hyperpho-
sphorylated Tau protein (P-Tau). Our recent data showed a differential accumulation of Tau protein phos-
phorylated at residue Thr231 (pThr231) in distinct hippocampal neurons in VLW mice—a model that over-
expresses mutated human Tau. Here we demonstrate that, in VLW mice, the accumulation of human P-Tau in
pyramidal cells induces the phosphorylation of murine Tau at residue Thr231 in hippocampal interneurons.
In addition, we show that pSer262 and pThr205 Tau are present specifically in the soma of some hippocampal
interneurons in control mice. Analysis of J20 mice—a model that accumulates Aβ—and of VLW animals showed
that the density of hippocampal interneurons accumulating pThr205 Tau is lower in VLW mice than in controls.
In contrast, the density of interneurons accumulating pThr205 Tau in J20 mice was increased compared to
controls in hippocampal regions with a higher Aβ plaque load, thereby suggesting that pThr205 Tau is induced
by Aβ. No significant differences were found between the density of hippocampal interneurons positive for
pSer262 Tau in VLW or J20 mice compared to control animals.
We also show that pSer262 and pThr205 Tau are present in the soma of some hippocampal interneurons
containing Parvalbumin, Calbindin or Calretinin in control, VLW, and J20 mice. Moreover, our results reveal
that some interneurons in human hippocampi of cases of AD and control cases accumulate pSer262 and pThr205
Tau. Taken together, these data point to a specific role of pSer262 and pThr205 Tau in the soma of hippocampal
interneurons in control and pathological conditions.
1. Introduction
Tau is a microtubule (MT)-associated protein that participates in
tubulin cytoskeleton assembly and stabilization (Drubin and Kirschner,
1986; Weingarten et al., 1975), and also in axonal transport regulation
and axon development, as well as in other less well-known functions in
the synapse (Ittner et al., 2010) and the nucleus (Sultan et al., 2011;
Violet et al., 2014). Certain factors can affect the unfolded conforma-
tion of Tau and promote its assembly in paired helical filaments (PHFs)
(Kidd, 1963), which leads to aggregation in neurofibrillary tangles
(NFTs), a feature of several neurodegenerative diseases (Lee et al.,
2001). Together with amyloid-β peptide (Aβ) species and plaques, Tau
in NFTs is one of the main histopathological hallmarks of Alzheimer's
disease (AD), the most common form of dementia (Ballatore et al.,
2007; Bloom, 2014; Haass and Selkoe, 2007).
Mutations can stimulate Tau aggregation, as is the case of familial
tauopathies like frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17) (Hutton et al., 1998). In addition, a wide
range of post-translational modifications of Tau, notably hyperpho-
sphorylation, can facilitate its aggregation (Kopke et al., 1993). Despite
these observations, data show that soluble Tau oligomers, not NFTs, are
the most toxic structures for neurons and synapses (Flach et al., 2012;
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SantaCruz et al., 2005; Tian et al., 2013; Yoshiyama et al., 2007).
In mature neurons, Tau is found mainly in the axon (Binder et al.,
1985) and only small amounts localize to dendrites (Papasozomenos
and Binder, 1987). However, the presence of Aβ oligomers, or Tau
hyperphosphorylation, mutations, or overexpression can cause the
mislocalization of this protein to the somatodendritic compartment and
may even drive it to postsynaptic spines under resting conditions, hence
producing excitatory synapse dysfunction (Frandemiche et al., 2014;
Götz et al., 1995; Hoover et al., 2010; Thies and Mandelkow, 2007). In
this regard, Tau appears to be required for Aβ-induced toxicity, as seen
both in vitro (Frandemiche et al., 2014; Jin et al., 2011; Zempel et al.,
2013) and in vivo (Ittner et al., 2010; Roberson et al., 2007, 2011). For
instance, missorted dendritic Tau mediates the synaptic impairment
induced by Aβ (Frandemiche et al., 2014; Ittner et al., 2010; Zempel
et al., 2013). In addition, a reduction in endogenous Tau levels in
human amyloid precursor protein (APP)-overexpressing mice protects
them against synaptic, network, and cognitive deficits (Roberson et al.,
2007, 2011).
Tau is a complex protein with more than 85 putative phosphor-
ylation sites (Hanger et al., 2007; Morishima-Kawashima et al., 1995).
Certain phosphoepitopes in Tau are recognized by antibodies that are
used as diagnostic markers of AD, including pThr205, pThr231 and
pSer262 (Goedert et al., 1994; Šimić et al., 2016). Phosphorylation at
residue Ser262 in the repeat domain of Tau greatly reduces its affinity
for MTs, but also prevents it from assembling into PHFs (Drewes et al.,
1995; Schneider et al., 1999; Sengupta et al., 1998). The effect of
pThr231 on the affinity of Tau for microtubules is less prominent;
primarily, this phosphoepitope in the proline-rich domain of Tau reg-
ulates the assembly of tubulin in MTs (Amniai et al., 2009; Cho and
Johnson, 2004; Sengupta et al., 1998). In addition, phosphorylation at
residues Thr231 and Ser262 may abnormally target Tau to dendritic
spines (Xia et al., 2015). Surprisingly, a protective effect against Aβ
toxicity has recently been proposed for pThr205 Tau (Ittner et al.,
2016). Therefore, the detailed functions of these phosphorylated re-
sidues in Tau are still unknown.
Our recent data demonstrate the presence of pThr231 Tau in hip-
pocampal GABAergic interneurons containing Parvalbumin (PV) in
VLW animals, a mouse model accumulating P-Tau (Lim et al., 2001;
Soler et al., 2017). Our results suggest that a dysfunction in hippo-
campal interneurons underlies the cognitive deficits associated with
tauopathies such as AD (Soler et al., 2017). In this regard, the dys-
function of GABAergic transmission was recently proposed as one of the
key factors in the pathogenesis of network dysfunction in AD (Busche
et al., 2015; Palop and Mucke, 2010), with PV-positive interneurons
possibly playing a prominent role. The function of neural circuits de-
pends on the synchronous activity of their components, and deregula-
tion of the excitatory/inhibitory balance seems to contribute to the
cortical network alterations and cognitive dysfunction associated with
AD (Palop and Mucke, 2016; Verret et al., 2012; Villette and Dutar,
2016).
Here we compared the distribution of several P-Tau forms, namely
pThr231, pSer262 and pThr205 Tau, in the hippocampus in normal and
pathological conditions in wild-type (WT), and in VLW and J20 mice,
which accumulate P-Tau and Aβ respectively (Lim et al., 2001; Mucke
et al., 2000), as well as in human samples. The soma of hippocampal
interneurons accumulated pSer262 and pThr205 in normal and pa-
thological conditions, thereby suggesting that Aβ induces Tau phos-
phorylation. These results point to a new role of P-Tau in hippocampal
GABAergic interneurons. This neuronal population thus emerges as a
new target for therapeutic approaches in AD.
2. Material and methods
2.1. Animals
To conduct the histological procedures, we used WT adult male
mice (C57BL/6J strain; 8-month-old (mo); n=4) and also 8 mo
transgenic adult male mice from two different lines presenting AD
features and with the same genetic background. In this regard, we used
VLW mice, which overexpress human Tau protein (hTau) with 4 tu-
bulin-binding repeats and 3 mutations related to FTDP-17: G272V (V),
P301L (L) and R406W (W) under the control of the Thy-1 promoter
(n=4). The second line was J20 mice, which overexpress the human
APP carrying two mutations, namely Swedish (K670N/M671L) and
Indiana (V717F) familial AD mutations (n=4).
All animals were kept on a 12-h light-dark schedule with access to
food and water ad libitum. All the animal experiments were performed
in accordance with the European Community Council Directive and the
National Institute of Health guidelines for the care and use of laboratory
animals. The local ethical committees also approved these experiments.
2.2. Human samples
Human samples from control subjects (n=2; 61 and 66 years old)
and AD patients (n=2; 73 and 91 years old, Braak IV-V) were provided
by Dr. Isidre Ferrer, from the Brain Bank of the Institute of
Neuropathology at Bellvitge Hospital in Barcelona (for more detailed
information see Supplementary Table 1). After the post-mortem in-
terval (PMI) indicated in Supplementary Table 1, the tissue was fixed
with 4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PB) for
24 h, and then cryoprotected with phosphate-buffered saline (PBS) with
30% sucrose. It was then frozen by a quick immersion in 2-methylbu-
tane at −50 °C, and 30 μm coronal sections were obtained by cryomi-
crotomy. Human samples were treated in accordance with the
European Community Council Directive and the National Institute of
Health guidelines.
2.3. Immunodetection
To obtain brain tissue, animals were deeply anesthetized by ad-
ministrating a lethal dose (400 μL per 60 g of weight) of a solution 10:1
of Ketolar® (ketamine hydrochloride 50mg/mL, Parke-Davis)/
Rompun® (2% xylazine-thiazine hydrochloride, Bayer). They were then
immediately perfused with 4% PFA in 0.1M PB. Next, the brains were
post-fixed for 48 h in 4% PFA and then cryoprotected with PBS with
30% sucrose at 4 °C. They were then frozen by a quick immersion in 2-
methylbutane at −50 °C, and 30 μm coronal sections were cut. These
were stored in a cryoprotectant solution (30% glycerol, 30% ethylene
glycol, 40% 0.1M PB) at −20 °C until use.
To detect the accumulation of hTau, pThr231, pSer262 or pThr205
Tau, tissue sections from WT, VLW and J20 mice were blocked for 2 h
and incubated overnight with HT7 mouse anti-hTau (ThermoFisher
Scientific; 1/500), AT-180 mouse anti-phosphothreonine 231
(Innogenetics; 1/300), S262 rabbit anti-phosphoserine 262
(Invitrogen™; 1/100), or T205 rabbit anti-phosphothreonine 205 anti-
bodies (Invitrogen™; 1/1000) at 4°C. Primary antibodies were visua-
lized by sequential incubation with biotinylated secondary antibodies
and ABC complex (2 h each; Vector Laboratories). The peroxidase re-
action was developed with diaminobenzidine (DAB), together with
nickel ammonium sulfate, cobalt chloride and H2O2 to intensify the
final signal. The sections were mounted onto gelatinized slides, dehy-
drated, and coverslipped with Eukitt® (O.Kindler). The same procedure
followed for the S262 and T205 antibodies was performed using human
samples from control subjects and AD patients.
Some mouse brain sections were also stained with 3D6 mouse anti-
APP antibody (obtained from the supernatant of cultured Murine
Hybridoma Cell Line, RB96 3D6.32.2.4 (PTA-5130), American Type
Culture Collection; 1/200) in order to detect the presence of senile
plaques in J20 mice. The primary antibody was visualized by sequential
incubation with DAB to produce a brown end product.
To determine whether hippocampal interneurons accumulated P-
Tau, several double fluorescent immunostainings were conducted using
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S262 or T205 and PV, Calbindin (CB) or Calretinin (CR) primary anti-
bodies. First, brain sections were blocked for 2 h and incubated over-
night simultaneously with goat anti-PV (1/3000), goat anti-CR (1/
3000) or mouse anti-CB (Swant®; 1/3000) antibodies and S262 or
T205. They were then incubated with Alexa Fluor 568 donkey anti-goat
or anti-mouse IgG against interneuron primary antibodies, whereas P-
Tau primary antibodies were targeted with Alexa Fluor 488 donkey
anti-rabbit IgG (Invitrogen™; 1/1000), for 2 h. Finally, brain sections
were mounted onto slides and coverslipped with Mowiol® (Merck).
To assess P-Tau induction, double fluorescent immunostainings
using AT-180 or HT7 antibodies combined with anti-PV antibody were
conducted.
Some sections were stained with T205 together with AT-180 anti-
bodies to detect the presence of both P-Tau forms in a single cell.
2.4. Image acquisition
Optical microscopy (Nikon E600, Nikon Corporation) observations
were focused on the immunohistochemically stained brain sections.
Images were acquired through a digital camera (Olympus DP72,
Olympus Corporation) coupled to the microscope and were processed
by Cell F^ software (Olympus Corporation).
Confocal microscopy (Leica TCS SP5, Leica Microsystems) ob-
servations were performed to acquire images from the immuno-
fluorescence-stained samples, using LAS AF software (Leica
Microsystems). The images were then processed by Fiji software
(Schindelin et al., 2012) to observe possible colocalization between the
interneurons and P-Tau markers.
2.5. Analysis of histological sections
To estimate the density of interneurons accumulating pSer262 or
pThr205 Tau, the samples stained with S262 or T205 antibodies were
scanned with a NanoZoomer 2.0HT whole slide imager (Hamamatsu
Photonics) at 20×. The density of pSer262 and pThr205 Tau-im-
munopositive interneurons was quantified in various regions and layers
of the hippocampal area (CA1, stratum oriens (so), stratum radiatum (sr),
stratum lacunosum moleculare (slm); CA3, so, sr; and DG, stratum mole-
culare (sm), stratum granulare (sg), hilus) of each section (4 animals/
genotype, 3–4 sections/animal). The cells and area comprising each
hippocampal region were quantified using Fiji software. The density of
immunopositive hippocampal cells was defined as the density of cells
per square millimeter.
To assess the percentage of Aβ plaque load in each hippocampal
region, the samples stained with 3D6 antibody were scanned with a
NanoZoomer 2.0HT whole slide imager at 20×. Later, the Trainable
Weka Segmentation plugin from Fiji software was applied to the images
by using a set of machine learning algorithms with a collection of image
features selected by the user to produce pixel-based segmentations. All
images were processed using a macro provided by Sebastién Tosi
(Institute for Research in Biomedicine, Barcelona) to identify and
quantify the amount of plaque present in a given hippocampal section
(4 animals, 4 sections/animal).
2.6. Statistical analysis of histological data
Histological data were processed for statistical analysis with
GraphPad Prism 6 (GraphPad Software Incorporated). To assess dif-
ferences between the experimental groups, overall comparisons,
namely one-way ANOVA and Kruskal-Wallis tests, were used when the
samples fitted a normal distribution or not, respectively. To determine
correlation between Aβ plaque load and density of pThr205 Tau-posi-
tive cells, the Pearson's r test was used. Significance was set at p < .05:
*p < .05, **p < .01, ****p < .0001. Statistical values are presented
as mean ± standard error of the mean (SEM).
3. Results
3.1. Tau phosphorylated at residue Thr231 is present in the soma of
hippocampal interneurons specifically in VLW mice
To analyze the pattern of Tau phosphorylation in the hippocampus
in control and pathological conditions, we first performed im-
munodetection of pThr231 Tau on hippocampal sections from 8 mo WT
mice, VLW mice, which accumulate hyperphosphorylated forms of Tau,
and J20 animals, which accumulate Aβ. As previously described (Lim
et al., 2001; Soler et al., 2017), VLW mice showed intense im-
munostaining in the soma and apical dendrites of pyramidal neurons in
CA1-3. In addition, as we previously described (Soler et al., 2017), the
soma of some hippocampal interneurons located mainly in the so also
accumulated pThr231 Tau (Fig. 1B). In contrast, WT and J20 mice did
not show pThr231-positive cells in any region of the hippocampus
(Fig. 1A, C). These data suggest that the overexpression of mutated
hTau in VLW mice has a direct effect on the accumulation of pThr231
Tau in hippocampal interneurons, absent in control mice and in J20
animals.
Fig. 1. pThr231 Tau is present in pyramidal neurons and hippocampal interneurons exclusively in VLW mice. Immunodetection of pThr231 Tau-immunopositive
cells in hippocampal sections from 8 mo WT, VLW and J20 mice. Tau protein phosphorylated at residue Thr231 detected with AT-180 antibody is not present in WT
(A) and J20 (C) hippocampi, whereas VLW mice (B) display pThr231 Tau-positive staining in the sp. and in several hippocampal neurons (arrows). Abbreviations: so,
stratum oriens; sp., stratum pyramidale; sr, stratum radiatum. Scale bar: 100 μm.
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3.2. Accumulation of pThr231 hTau in pyramidal cells induces pThr231
murine Tau in PV-positive hippocampal interneurons in VLW mice
VLW mice overexpress mutated hTau under the Thy-1 promoter,
which leads to the accumulation of P-Tau mainly in pyramidal neurons
in the hippocampus (Lim et al., 2001). Moreover, we previously de-
monstrated an accumulation of pThr231 Tau in PV-positive hippo-
campal interneurons in VLW mice (Soler et al., 2017).
To determine whether the presence pThr231 Tau in hippocampal
interneurons in VLW mice is due to an overexpression of mutated hTau
in these cells or to intercellular P-Tau induction, we first detected
specifically hTau by the use of HT7 antibody in WT, VLW and J20
hippocampi. Our data confirmed that WT and J20 mice did not accu-
mulate hTau (Supplementary Fig. 1A-B, E-F), and indicated that only
pyramidal neurons in CA1–3 expressed hTau in VLW animals
(Supplementary Fig. 1C, D). No signal was observed in neurons outside
the pyramidal cell layer, indicating that hippocampal interneurons did
not express hTau in VLW mice. In order to confirm this observation, we
performed double fluorescent immunodetection on hippocampal sec-
tions from 8 mo VLW mice. Using an anti-PV antibody to detect hip-
pocampal interneurons combined with anti-pThr231 Tau or with HT7,
which specifically detects hTau, we found that PV-positive interneurons
accumulated pThr231 Tau but not hTau (Fig. 2A–F). These observations
indicate that the accumulation of mutated hTau in pyramidal neurons
induces the phosphorylation of endogenous Tau at residue Thr231 in
PV-positive interneurons in VLW mice, thereby demonstrating an in-
tercellular spread of P-Tau in vivo.
3.3. Hippocampal interneurons accumulate P-Tau at residues Ser262 and
Thr205 in their soma in non-pathological conditions
Tau hyperphosphorylation is associated with AD and other neuro-
degenerative conditions (Iqbal et al., 2016; Khan and Bloom, 2016);
however, the physiological functions of Tau are also regulated by
phosphorylation. In fact, Tau phosphorylation at different sites could
have different outcomes for each Tau function (Avila, 2009; Medina
et al., 2016). Some phosphorylated Tau residues are related to neuro-
degenerative processes in humans, but their importance in non-patho-
logical conditions is not clear. To analyze the phosphorylation of Tau in
physiological conditions, we performed immunohistochemistry against
pSer262 and pThr205 Tau on hippocampal sections from 8 mo WT
mice. Our results revealed that some hippocampal neurons located in
the so and sr of CA1-3 (Fig. 3A, B) and also scattered in the sg and in the
hilus of the dentate gyrus (DG, Fig. 3C) showed pSer262 Tau-im-
munopositive staining in their soma. In addition, some pThr205 Tau-
positive cells were also present in the so and sr of CA1-3, and dispersed
in the sg, sm and in the hilus of the DG (Fig. 3D-F). The distribution and
morphology of these cells appeared to correspond to hippocampal in-
terneurons. Using double immunodetection of pSer262 and pThr205
Tau with hippocampal GABAergic neuron markers such as PV, CB and
CR, we show that the pSer262 and pThr205 Tau-positive cells corre-
spond to GABAergic hippocampal cells containing PV, CB and CR
(Fig. 4A-I). We quantified the presence of P-Tau forms in PV-im-
munopositive cells, the main population of GABAergic hippocampal
cells. In the PV-positive cell population, 62% of the cells accumulated
pSer262 Tau and 58% of them presented pThr205 Tau. These data
demonstrate that pSer262 and pThr205 Tau accumulate in the soma of
hippocampal interneurons in non-pathological conditions.
Fig. 2. Human P-Tau accumulated in pyramidal neurons induces murine pThr231 Tau in PV-positive hippocampal interneurons in VLW mice. Double immuno-
fluorescent detection of P-Tau or hTau and interneuron marker PV in the CA1 region in hippocampal sections from 8 mo VLW mice. (A) Accumulation of Tau
phosphorylated at residue Thr231 in hippocampal cells, detected with AT-180 antibody (arrows). (B and E) Detection of PV-positive hippocampal interneurons. (C)
Colocalization of pThr231 Tau with PV-positive interneurons (arrows). (D) Expression of hTau in hippocampal cells, detected with HT7 antibody. (F) No coloca-
lization of hTau and PV-positive interneurons. Abbreviations: PV, Parvalbumin; so, stratum oriens; sp., stratum pyramidale; sr, stratum radiatum. Scale bars: in C, 50 μm
(applies to A-C); in F, 25 μm (applies to D-F).
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3.4. The distribution and density of pSer262 Tau-positive hippocampal
interneurons are similar in WT, VLW and J20 mice
To study whether pSer262 Tau accumulation in the soma of hip-
pocampal interneurons is also present in pathological conditions, we
next compared pSer262 Tau immunodetection on hippocampal sections
from WT animals with those of VLW and J20 mice. Like the hippocampi
of WT animals, those of VLW and J20 mice showed some scattered
neurons in the so and sr of CA1-3 (Fig. 5B-C, F-G), and in the hilus, sg
and sm of the DG (Fig. 5J-K). Therefore, we studied the density of
pSer262 Tau-positive cells by comparing WT mice with VLW and J20
animals. No differences in the density of interneurons accumulating
pSer262 Tau in the hippocampus were detected between the three
animal models. Neither were differences observed when CA1, CA3 and
the DG were analyzed separately (Fig. 5D, H, L).
Thus, our data show that there are no differences in the distribution
pattern of pSer262 Tau or in the density of cells accumulating this P-
Tau form in the hippocampus between normal and pathological con-
ditions. These results indicate that pSer262 accumulation in the soma of
hippocampal interneurons is independent of the Aβ or P-Tau present in
the hippocampus.
3.5. The density of pThr205 Tau-immunopositive hippocampal interneurons
decreases in VLW mice
Next, we compared pThr205 Tau accumulation in the hippocampus
of VLW and WT mice. In contrast to data on pSer262 Tau, differences
were detected in the distribution of pThr205 Tau-positive cells between
the normal and the pathological models. In this regard, there was a
clear accumulation of pThr205 Tau in VLW pyramidal cells while this
was not observed in WT animals (Fig. 6A, B). VLW mice overexpress
mutated hTau mostly in these cells, thus accumulating P-Tau in the
pyramidal layer (Lim et al., 2001; Soler et al., 2017).
In addition to pyramidal cells, some mossy cells and several
interneurons, mainly in the so and sr, accumulated pThr205 Tau in the
hippocampus of VLW mice (Fig. 6A-B, E-F, I-J). We then analyzed the
number of pThr205 Tau-positive cells in distinct hippocampal regions.
The density of pThr205 Tau-positive cells in VLW mice was lower than
in age-matched WT mice, mainly in CA1 and CA3 regions (45% and
47% of reduction respectively, Fig. 6D, H, L). Nevertheless, regarding
the density of pThr205 Tau-positive cells in the DG, no differences were
found between the WT and VLW mice (Fig. 6L; 112.5 ± 12.6 and
87.6 ± 9.4, respectively).
Our previous data (Soler et al., 2017) demonstrated that some PV-
positive interneurons, the most abundant subtype of hippocampal in-
terneurons (Freund and Buzsaki, 1996; Matyas et al., 2004), accumu-
lated pThr231 Tau in VLW mice (Soler et al., 2017). It has been de-
scribed that Tau phosphorylation at specific residues depends on
phosphorylation at other Tau epitopes (Ando et al., 2016). We therefore
examined whether the decrease in Thr205 Tau phosphorylation in VLW
mouse interneurons was due to the presence of pThr231 Tau in PV-
positive interneurons. By means of double immunodetection using the
AT-180 antibody against pThr231, and the T205 antibody against
pThr205 (Fig. 7), we demonstrated colocalization between T205 and
AT-180 staining in some hippocampal interneurons located mainly in
the so, but also in pyramidal neurons (Fig. 7A-C). Therefore, some
neurons in VLW mice accumulated pThr231 and pThr205 Tau si-
multaneously. This observation thus suggests that pThr231 Tau does
not repress the phosphorylation of Tau at residue Thr205.
3.6. The density of pThr205 Tau-immunopositive hippocampal interneurons
increases in the presence of Aβ accumulation in J20 animals
Analysis of the hippocampi of J20 mice subsequently demonstrated
the presence of intensely immunostained pThr205 Tau-positive cells in
the so and sr of the CA1-3 and in the hilus and sm of the DG (Fig. 6C, G,
K). Comparison of the number of pThr205 Tau-positive interneurons in
J20 and WT animals showed an almost 1.5-fold increase in the density
Fig. 3. Distribution pattern of pSer262 and pThr205 Tau-positive cells in WT mice. Immunodetection of pSer262 and pThr205 Tau-immunopositive cells in hip-
pocampal sections from 8 mo WT mice. (A-C) The soma of hippocampal cells in the CA1 (A), CA3 (B) and DG (C) regions accumulate pSer262 Tau. (D-F) The soma of
hippocampal cells in the CA1 (D), CA3 (E) and DG (F) regions accumulate pThr205 Tau. Abbreviations: h, hilus; sg, stratum granulare; sm, stratum moleculare; so,
stratum oriens; sp., stratum pyramidale; sr, stratum radiatum. Scale bar: 100 μm.
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of these cells in the so of the CA1 (Fig. 6D; WT: 263.7 ± 7.6 and J20:
393.7 ± 39.3; p= .0104) and a 2-fold increase in the DG (Fig. 6L; WT:
112.5 ± 12.6 and J20: 224.5 ± 35.0; p= .0203) of J20 mice. No
differences were found in the sr+ slm of the CA1 or in the CA3 when
compared with WT data (Fig. 6D, H). Furthermore, neither were dif-
ferences in the density of pThr205 Tau-positive cells detected in the
hilus (WT: 606.5 ± 77.1 and J20: 833.8 ± 139.1; p= .194). Given
that mossy cells are the most abundant population in this region, the
differences observed in the DG appear to correspond mainly to an in-
crease in the density of pThr205 Tau-positive interneurons.
A number of studies have demonstrated how Aβ influences Tau
hyperphosphorylation (Forner et al., 2017; Götz et al., 2001; Ittner and
Götz, 2011). Given that the increase in the density of pThr205 Tau-
positive cells in J20 mice with respect to WT animals was not
homogeneous in all hippocampal regions (Fig. 6D, L), the percentage of
increase was calculated in CA1, CA3 and DG independently. Con-
sidering that the so showed statistical differences only in the CA1
(Fig. 6D), the distinct strata of this region were studied separately.
Comparison of J20 mice with control animals revealed that the CA1 so
(33.0 ± 1.9%) and the DG (45.4 ± 5.6%) displayed the highest per-
centage of increase in the density of pThr205 Tau-positive cells, while
the CA1 sr, together with the CA1 slm (sr+ slm) and the CA3, showed
only a slight increase (7.1 ± 3.1% and 5.5 ± 3.9%, respectively).
Statistical analysis showed a significant increase in the so of the CA1
and in the DG compared with the sr+ slm of the CA1 and with the CA3
(Fig. 8A). These data indicate a differential increase in the density of
pThr205 Tau-positive cells in distinct hippocampal regions.
To determine whether these specific increases in the DG and so of
Fig. 4. WT mice accumulate pSer262 and pThr205 Tau in PV-, CR- and CB-positive hippocampal interneurons. Double immunofluorescent detection of pSer262 or
pThr205 Tau and interneuron markers PV, CR and CB in hippocampal sections from 8 mo WT mice. (A-F) PV-, CR- and CB-positive hippocampal interneurons (red)
accumulate Tau phosphorylated at residue Thr205 (green) in 8 mo WT mice. Colocalization of pThr205 Tau with PV- (arrows in C) and CR-positive (arrows in F)
interneurons. (G-I) PV-, CR- and CB-positive hippocampal interneurons (red) accumulate Tau phosphorylated at residue Ser262 (green) in 8 mo WT mice.
Colocalization of pSer262 Tau with CB-positive (arrows in I) interneurons. Abbreviations: CB, Calbindin; CR, Calretinin; PV, Parvalbumin; so, stratum oriens; sp.,
stratum pyramidale; sr, stratum radiatum. Scale bar: 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
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the CA1 region correlate with the presence of Aβ plaques, we performed
3D6 immunostaining. As previously described (Furcila et al., 2018), Aβ
plaques accumulated in the CA1 and DG regions (Fig. 8C), accounting
for 35% and 47% of the Aβ in the hippocampus (Fig. 8B). Our results
showed a high degree of correlation between the increase in pThr205
Tau-positive cells and the presence of Aβ plaques (Fig. 8D).
Taken together, these results demonstrate that the regions that
showed an increase in cells accumulating pThr205 Tau correlated with
those with a higher Aβ plaque load, thereby pointing to an inductive
effect of Aβ in the phosphorylation of Tau at residue Thr205.
3.7. The soma of PV-, CR- and CB-positive hippocampal interneurons
accumulate pSer262 and pThr205 Tau in VLW and J20 mice
Our data established that pSer262 and pThr205 Tau were present in
the soma of some neurons scattered throughout the hippocampus in
normal and pathological conditions. To identify the hippocampal in-
terneuron populations that accumulated both P-Tau forms, we per-
formed a double immunodetection using PV, CB or CR interneuron
markers and S262 or T205 antibodies in brain sections from VLW and
J20 mice. Our results revealed colocalization between the hippocampal
interneuron markers PV, CR and CB and the S262 (Fig. 9D-F, G-I) or
T205 (Fig. 9A-C, J-L) antibody signal.
These findings therefore indicate that both pSer262 and pThr205
Tau accumulate in hippocampal PV-, CR- and CB-positive interneurons
in VLW and J20 mice, as previously observed in WT animals.
3.8. pSer262 and pThr205 Tau accumulate in human hippocampal
interneurons in normal and pathological conditions
Our data demonstrated the presence of pSer262 and pThr205 Tau in
the soma of hippocampal interneurons in both WT animals and pa-
thological mouse models of AD. We therefore addressed whether
human hippocampal interneurons also accumulate pSer262 Tau and
pThr205 Tau. To this end, we analyzed human hippocampal sections
from two control subjects and from two AD patients (Braak IV-V). Using
immunohistochemistry against pSer262 and pThr205 Tau, we demon-
strated that several human hippocampal neurons showed an im-
munopositive signal for pSer262 (Fig. 10A, B) or pThr205 Tau
(Fig. 10C, D) in normal and pathological conditions. The pSer262 and
pThr205 Tau-positive cells were large multipolar neurons located out-
side the pyramidal and granular cell layers, mainly in the sr and so. The
location and morphological characteristics of cells accumulating
pSer262 or pThr205 Tau seemed to correspond to interneurons. Al-
though the staining in hippocampal interneurons differed from the
NFTs observed in pyramidal neurons in AD samples, these P-Tau forms
had different cellular distributions. The pSer262 Tau staining was
spread evenly within the entire neuron and was higher in AD samples.
In contrast, the pThr205 Tau staining was homogeneously distributed,
but it also formed somatic clusters both in control and AD samples.
On the basis of our findings, we conclude that pSer262 and pThr205
Tau accumulate in hippocampal interneurons in mice and human sub-
jects in normal and pathological conditions.
Fig. 5. Distribution pattern and cell density quantification of pSer262 Tau-positive cells in WT, VLW and J20 mice. Immunodetection and cell density quantification
of pSer262 Tau-immunopositive cells in hippocampal sections from 8 mo WT, VLW and J20 mice. (A-C, E-G and I-K) pSer262 Tau accumulation in hippocampal
interneurons (arrows) located in different areas of the CA1 (A-C), CA3 (E-G) and DG (I-K) regions, and in mossy cells (arrowheads) of the DG (I-K), noting a stronger
immunostaining in the cells located in the so of J20 mice (C) compared to WT mice (A). (D, H and L) Density quantification of immunopositive interneurons in each
region, cell densities being generally higher in WT and J20 mice compared to VLW mice. For (D), (H) and (L): one-way ANOVA. n=4 animals/genotype, 3–4
sections/animal. Error bars represent SEM. Abbreviations: h, hilus; sg, stratum granulare; sm, stratum moleculare; so, stratum oriens; sp., stratum pyramidale; sr, stratum
radiatum. Scale bar: 100 μm.
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4. Discussion
4.1. pThr231 hTau in pyramidal cells induces pThr231 murine Tau in PV-
positive hippocampal interneurons specifically in VLW mice
Our previous studies (Soler et al., 2017) demonstrated that hippo-
campal neuron populations accumulate distinct forms of P-Tau in VLW
mice, an animal model that overexpresses mutated hTau. This model
shows an accumulation of pThr231 Tau in pyramidal cells, mossy cells
and PV-positive interneurons. Our present data indicate that only pyr-
amidal neurons in VLW mice express hTau; in addition, we show that
the pThr231 Tau-positive signal is absent in WT hippocampi, thereby
suggesting a specific effect of P-Tau accumulation on the phosphor-
ylation of Tau in hippocampal interneurons.
P-Tau aggregates spread and replicate in a prion-like manner. It has
been shown, mainly in cell culture experiments, that the uptake of
pathological Tau seeds causes hyperphosphorylation, misfolding and
aggregation of monomeric Tau in recipient cells (Clavaguera et al.,
Fig. 6. Distribution pattern and cell density quantification of pThr205 Tau-positive cells in WT, VLW and J20 mice. Immunodetection and cell density quantification
of pThr205 Tau-immunopositive cells in hippocampal sections from 8 mo WT, VLW and J20 mice. (A-C, E-G and I-K) pThr205 Tau accumulation in hippocampal
interneurons (arrows) located in different areas of the CA1 (A-C), CA3 (E-G) and DG (I-K) regions, and in mossy cells (arrowheads) of the DG (I-K), noting a stronger
immunostaining in the sp of VLW mice (B) compared to WT mice (A). (D, H and L) Density quantification of immunopositive interneurons in each region, cell
densities being generally higher in WT and J20 mice compared to VLW mice. For (D), (H) and (L): one-way ANOVA, *p < .05. n=4 animals/genotype, 3–4
sections/animal. Error bars represent SEM. Abbreviations: h, hilus; sg, stratum granulare; sm, stratum moleculare; so, stratum oriens; sp., stratum pyramidale; sr, stratum
radiatum. Scale bar: 100 μm.
Fig. 7. Hippocampal interneurons and pyramidal cells accumulate both pThr231 and pThr205 Tau in 8 mo VLW mice. Double immunofluorescent detection of
pThr231 and pThr205 Tau in 8 mo VLW mice showed hippocampal interneurons located in the stratum oriens (so) and pyramidal neurons accumulating Tau
phosphorylated at residue Thr205 (red, A) and pThr231 (green, B). Colocalization of pThr205 with pThr231 Tau (arrows in C) in hippocampal interneurons. Scale
bar: 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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2009; Polanco et al., 2016; Wang et al., 2017). Here we describe in vivo
that overexpression of mutated hTau in pyramidal neurons induces the
phosphorylation of murine Tau at residue Thr231 in PV-positive hip-
pocampal interneurons.
4.2. Hippocampal interneurons and mossy cells accumulate pSer262 Tau in
control and pathological conditions
Our results show that pSer262 Tau accumulates in the soma of PV-,
CR- and CB-positive interneurons and mossy cells in WT, VLW and J20
mice. Nevertheless, Tau is normally located in the axon, although lower
levels are also present in the somatodendritic compartment and nucleus
(Avila et al., 2004; Hernández and Avila, 2007). Many studies have
reported the development of non-typical functions of Tau protein
alongside the dendritic spines or even in the nucleus. These functions
include maintenance of the integrity of genomic DNA, and cytoplasmic
and nuclear RNA, as well as the regulation of NMDA receptors and
synaptic plasticity (Guo et al., 2017; Sotiropoulos et al., 2017).
In addition, pSer262 Tau has been described as pathological and
used as a diagnostic marker for AD (Braak et al., 2011; Šimić et al.,
2016; Wang and Mandelkow, 2016). Several studies have reported the
capacity of Aβ to induce Tau hyperphosphorylation (Bolmont et al.,
2007; Götz et al., 2001; Stancu et al., 2014), as well as the relevance of
the same P-Tau forms in promoting the same effect on other Tau mo-
lecules, hence increasing the P-Tau burden (Šimić et al., 2016). Given
that our data suggest that the phosphorylation of residue Ser262 is not
influenced by the presence of hyperphosphorylated forms of Tau in
VLW animals or by the accumulation of Aβ in J20 mice, it would appear
that pSer262 Tau in the soma of hippocampal interneurons and mossy
cells has a specific function that is independent of AD pathology.
On the basis of our results, we propose that Tau shows distinct
patterns of phosphorylation in hippocampal interneurons and mossy
cells, possibly in order to exert functions other than those performed
exclusively in the axon. Our data reinforce the notion that, despite
being considered pathological (Guo et al., 2017), pSer262 Tau is not
induced by the accumulation of P-Tau or Aβ.
4.3. The presence of P-Tau and Aβ influences the accumulation of pThr205
Tau in hippocampal interneurons
Our results show that the soma of PV-, CR- and CB-positive inter-
neurons and mossy cells accumulate pThr205 Tau in WT, VLW and J20
mice. These data point to a physiological role of pThr205 Tau in the
somatic region of hippocampal interneurons and mossy cells. In addi-
tion, our findings reveal a significant decrease in the density of pThr205
Tau-positive cells in the CA1 and CA3 regions of VLW mice. As pre-
viously described, pThr231 Tau accumulates only in PV-positive cells in
the hippocampal interneuron population (Soler et al., 2017). Likewise,
other studies have stated that the phosphorylation of specific residues
may influence—by inducing or repressing—phosphorylation in other
regions or domains of Tau (Ando et al., 2016). Our results reveal that
pThr231 and pThr205 Tau coexist in a single cell, thereby suggesting
Fig. 8. Increases in the density of pThr205 Tau-positive cells and correlation to the distribution pattern of Aβ plaques in J20 mice. Subfield-specific increases in
density of pThr205 Tau-positive cells and Aβ plaque load in hippocampal sections from 8 mo J20 mice. (A) Quantification of the percentage increase in the density of
pThr205 Tau-positive cells, compared to WT mice, in distinct hippocampal subfields. (B) Quantification of the percentage of Aβ plaques in distinct hippocampal
subfields. (C) Aβ accumulation in different areas of the hippocampus, detected with the 3D6 antibody, displaying the presence of higher plaque loads in the so of CA1
and in the DG. (D) Correlation analysis between percentages of Aβ plaques and increases in the density of pThr205 Tau-positive cells in different areas of the
hippocampus. For (A) and (B): one-way ANOVA, *p < .05, **p < .01, ****p < .0001. For (D): Pearson's r=0,989. n=4 animals/genotype, 4 sections/animal.
Error bars represent SEM. Abbreviations: slm, stratum lacunosum moleculare; so, stratum oriens; sr, stratum radiatum. Scale bar: 500 μm.
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Fig. 9. VLW and J20 mice accumulate pSer262 and pThr205 Tau in PV-, CR- and CB-positive hippocampal interneurons. Double immunofluorescent detection of
pSer262 or pThr205 Tau and interneuron markers PV, CR and CB in hippocampal sections from 8 mo VLW and J20 mice. (A-C and J-L) PV-, CR- and CB-positive
hippocampal interneurons (red) accumulate Tau phosphorylated at residue Thr205 (green). Colocalization of pThr205 Tau with PV- (arrows in C) and CB-positive
(arrows in L) interneurons. (D-I) PV-, CR- and CB-positive hippocampal interneurons (red) accumulate Tau phosphorylated at residue Ser262 (green). Colocalization
of pSer262 Tau with PV- (arrows in F) and CR-positive (arrows in I) interneurons. Abbreviations: CB, Calbindin; CR, Calretinin; PV, Parvalbumin; so, stratum oriens;
sp., stratum pyramidale; sr, stratum radiatum. Scale bar: 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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that the former does not suppress the latter.
Our present data demonstrate that hTau expressed in pyramidal
cells in VLW mice induces the phosphorylation of murine Tau at residue
Thr231 in PV-positive interneurons. Therefore, we cannot discard the
possibility that hyperphosphorylated hTau accumulated in the pyr-
amidal cells of VLW mice represses the phosphorylation of murine Tau
at residue Thr205 in hippocampal interneurons, thereby reducing the
density of pThr205 Tau-positive interneurons.
In addition, many Tau residues, such as Thr205, are dependent on
Glycogen Synthase Kinase 3 (GSK3) (Guo et al., 2017), a kinase that
requires the previous (primed) phosphorylation of other Ser/Thr sites
on its substrates, following a certain pattern, to exert its function
(Medina et al., 2011; Sutherland, 2011). Hence, it cannot be discarded
that VLW mice, a model of Tau hyperphosphorylation, show altered
priming patterns of Tau phosphorylation, thus impeding GSK3 from
correctly phosphorylating Tau at residue Thr205.
In contrast to the results obtained in VLW mice, J20 animals showed
a significant increase in the density of cells accumulating pThr205 Tau
in the CA1 so and DG with respect to WT mice.
Aβ induces Tau hyperphosphorylation (Bolmont et al., 2007; Götz
et al., 2001; Stancu et al., 2014). Our data indicate that the regions that
show an increase in the number of cells accumulating pThr205 Tau
correlate with those that display a higher Aβ plaque load, thereby
suggesting an inductive effect of Aβ in the phosphorylation of Tau at
residue Thr205. Thus, these data imply that the increase in the density
of hippocampal interneurons accumulating pThr205 Tau in J20 mice
could be a consequence of an inductive effect of Aβ on Tau
phosphorylation. It has recently been described that the specific phos-
phorylation of Tau at residue Thr205 inhibits Aβ neurotoxicity (Ittner
et al., 2016). This observation contrasts with the current view that Tau
phosphorylation downstream of Aβ toxicity is a pathological response.
Thus, given that GABAergic hippocampal neurons appear to be resistant
to neurotoxicity in AD (Canas et al., 2014; Mitew et al., 2013;
Reinikainen et al., 1988; Rissman et al., 2007), our data showing an
inductive effect of Aβ on Tau phosphorylation at residue Thr205 in
hippocampal interneurons could reflect a reaction in hippocampal in-
terneurons to protect themselves from neurotoxicity.
4.4. The soma of some human hippocampal interneurons accumulate
pSer262 and pThr205 Tau in control subjects and AD patients
After observing that pSer262 and pThr205 Tau are present in hip-
pocampal interneurons in physiological conditions, and that the
number of cells accumulating pThr205 Tau increases in the presence of
Aβ, we analyzed human hippocampal interneurons.
Our data show that human control and AD samples show few neu-
rons accumulating pSer262 and pThr205 Tau in their soma in the sr and
so. Despite the limited number of human samples analyzed, the location
and morphology of pSer262 and pThr205 Tau-positive human neurons
seem to correspond to hippocampal interneurons. Therefore, these re-
sults suggest that human hippocampal interneurons accumulate
pSer262 and pThr205 Tau in control and pathological conditions. Thus,
the presence of pSer262 and pThr205 Tau in the soma of interneurons
in murine hippocampi is also detected in control and pathological
Fig. 10. pSer262 and pThr205 Tau accumulate in the soma of hippocampal interneurons in non-pathological and AD human subjects. Immunodetection of pSer262
or pThr205 Tau in the sr and slm in hippocampal sections from non-pathological and AD human subjects. (A and C) The soma of interneurons in non-pathological
hippocampi accumulate pSer262 (A) and pThr205 (C) Tau. (B and D) The soma of hippocampal interneurons of AD patients accumulate pSer262 (B) and pThr205 (D)
Tau. Scale bar: 50 μm.
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human samples.
Our results reveal a differential pattern of phosphorylation and
distribution of P-Tau in hippocampal interneurons and mossy cells. The
data suggest that Tau protein acts differently in these neuronal popu-
lations, developing yet unknown additional functions in the soma. In
addition, the presence of P-Tau and Aβ influences the accumulation of
pThr205 Tau in hippocampal interneurons, thereby supporting the
notion that pThr205 Tau probably protects against Aβ in AD.
Recently, various therapeutic approaches to AD have attempted to
decrease the P-Tau as a strategy to prevent Aβ toxicity (Medina, 2018;
Pedersen and Sigurdsson, 2015). Our present data point to a physio-
logical role of pSer262 and pThr205 Tau in the soma of hippocampal
interneurons and that these phosphorylations are modulated by the
presence of Aβ. Thus, our results evidence that caution must be taken
when pharmacological modulation of Tau phosphorylation is proposed
as a treatment for AD. A deeper understanding of the dynamics of Tau
phosphorylation on the distinct hippocampal neuronal types may con-
tribute to the design of new therapies for AD and other tauopathies. In
this context, research into the behavior of Tau in hippocampal inter-
neurons may broaden current knowledge of Tau function and impair-
ment, and may also help to determine the potential of interneurons as a
therapeutic target to halt the cognitive impairment associated with AD.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2018.12.006.
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